A Phase 2b, Randomized, Controlled, Open-label Study to Evaluate the Immune Response and Safety of the RSVPreF3 OA Investigational Vaccine in Adults (#50 years of age) When Administered to Lung and Renal Transplant Recipients Comparing 1 Versus 2 Doses an

Grants and Contracts Details

StatusActive
Effective start/end date10/31/2310/31/25

Funding

  • GlaxoSmithKline: $82,394.00